Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBunzl Regulatory News (BNZL)

Share Price Information for Bunzl (BNZL)

Share Price is delayed by 15 minutes
Get Live Data
2,464.00    -6.00 (-0.24%)
Bid:
2,462.00
Ask:
2,466.00
Spread: 4.00 (0.162%)
Market Cap: £7.91b
BNZL Live PriceLast checked at - London Stock Exchange

Intraday Bunzl Share Chart

Trading Statement

26 Oct 2021 07:00

RNS Number : 1860Q
Bunzl PLC
26 October 2021
 

26 October 2021

BUNZL Q3 TRADING STATEMENT

 

Bunzl plc, the specialist international distribution and services Group, today announces its trading statement for the period since 30 June 2021.

 

Bunzl's diversified and resilient business model has delivered strong overall growth against a background of continuing pandemic-related challenges. Group revenue for the third quarter was 7.8% higher year-on-year at actual exchange rates, an increase of 13.0% at constant exchange rates. Acquisitions contributed revenue growth of 4.3% at constant exchange rates, while a greater number of trading days than the comparable period in 2020 further benefited revenue growth by 6.2% although this will unwind in the fourth quarter. Underlying revenue growth at constant exchange rates was 2.5%. Group adjusted operating margin was, as expected, impacted by ongoing deflation in certain Covid-19 related products.

 

Within underlying revenue growth of 2.5%, the strong recovery in the base business contributed underlying sales growth of 12.0%, with broad strength across business areas and continued support of product inflation particularly in North America. This growth was largely offset by a 9.4% impact on underlying growth from a decline in sales of top 8 Covid-19 related products, which are primarily own brand. Underlying revenue for the third quarter was approximately 10% higher than the comparable 2019 period.

 

With good revenue performance year to date the Group now expects slight underlying revenue growth in 2021 compared to 2020 at constant exchange rates. Given the strength of performance in 2020 revenue is expected to demonstrate good underlying growth compared to 2019, highlighting the quality and resilience of the Bunzl business model. Margin expectations for the year are unchanged, with adjusted operating margin expected to be only slightly ahead of historical levels. With 2021 continuing to reflect pandemic-related dynamics, we continue to expect to see a further normalisation of Group operating margin in 2022 to more historical levels, as the mix of sector and product sales returns to more typical levels for the Group.

 

The Group also announces today that at the end of September it completed the acquisition of Intergro LLC ("Intergro"), a distributor of agricultural supplies to commercial growers in the Eastern US with a strong own brand portfolio. Intergro generated revenue of £17 million in 2020 and is complementary to our existing agriculture business in North America. The Group also completed the previously announced acquisition of McCue Corporation during October following competition clearance.

 

Frank van Zanten, Chief Executive Officer of Bunzl, commented:

 

"At our recent Capital Markets Day, as well as providing insights into the opportunity that sustainability presents to Bunzl, we highlighted the strength of our compounding strategy which has delivered strong shareholder returns for many years. This track record of success continues with another good trading performance in Q3 and the acquisition of Intergro, which is our 11th acquisition year to date. Intergro is complementary to our existing agricultural business and broadens the Group's product offering to customers. Our acquisition pipeline remains active, supported by the strength of our balance sheet."

 

 

Enquiries:

Bunzl plc

Frank van Zanten, Chief Executive Officer

Richard Howes, Chief Financial Officer

Sunita Entwisle, Head of Investor Relations

Tel: +44 (0)20 7725 5000

Tulchan

Martin Robinson

Olivia Peters

Tel: +44 (0)20 7353 4200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBUBDGLSDDGBU
Date   Source Headline
7th Jul 20219:30 amRNSDirector/PDMR Shareholding
1st Jul 202112:30 pmRNSTotal Voting Rights
24th Jun 20217:00 amRNSTrading Statement
23rd Jun 20218:00 amRNSAdditional Listing
3rd Jun 20211:00 pmRNSDirector/PDMR Shareholding
1st Jun 20211:00 pmRNSTotal Voting Rights
26th May 20219:30 amRNSDirector Declaration
26th May 20218:00 amRNSAdditional Listing
18th May 20217:00 amRNSAcquisition
6th May 202110:40 amRNSDirector/PDMR Shareholding
5th May 20211:15 pmRNSDirector/PDMR Shareholding
5th May 20211:01 pmRNSDirector/PDMR Shareholding
4th May 202110:50 amRNSTotal Voting Rights
4th May 20219:25 amRNSBlock listing Interim Review
22nd Apr 20214:40 pmRNSDirector/PDMR Shareholding
21st Apr 20214:16 pmRNSResult of AGM
21st Apr 20217:00 amRNSTrading Statement
14th Apr 202111:45 amRNSDirector/PDMR Shareholding
12th Apr 20218:43 amRNSDirector/PDMR Shareholding
12th Apr 20218:24 amRNSDirector/PDMR Shareholding
7th Apr 20213:24 pmRNSDirector/PDMR Shareholding
1st Apr 202111:44 amRNSTotal Voting Rights
31st Mar 20215:34 pmRNSDirector/PDMR Shareholding
22nd Mar 20214:30 pmRNSDirector Declaration
17th Mar 20214:27 pmRNSAnnual Financial Report
8th Mar 20215:53 pmRNSDirector/PDMR Shareholding
5th Mar 20211:10 pmRNSDirector/PDMR Shareholding
4th Mar 20215:33 pmRNSDirector/PDMR Shareholding
3rd Mar 202110:00 amRNSDirector Declaration
1st Mar 20212:00 pmRNSTotal Voting Rights
1st Mar 20211:00 pmRNSDirector/PDMR Shareholding
1st Mar 20211:00 pmRNSDividend Declaration
1st Mar 20217:00 amRNSFinal Results
1st Mar 20217:00 amRNSAcquisition
1st Feb 202110:00 amRNSTotal Voting Rights
20th Jan 20217:00 amRNSDirector Declaration
6th Jan 20214:00 pmRNSDirector/PDMR Shareholding
4th Jan 202111:50 amRNSTotal Voting Rights
22nd Dec 20207:00 amRNSDirectorate Change
16th Dec 20208:00 amRNSAdditional Listing
16th Dec 20207:00 amRNSTrading Statement
9th Dec 20208:00 amRNSAdditional Listing
3rd Dec 20209:27 amRNSDirector/PDMR Shareholding
2nd Dec 20208:00 amRNSAdditional Listing
1st Dec 202011:57 amRNSTotal Voting Rights
20th Nov 202012:30 pmRNSDirector Declaration
9th Nov 20207:00 amRNSAcquisition
3rd Nov 20205:18 pmRNSDirector/PDMR Shareholding
2nd Nov 202010:45 amRNSTotal Voting Rights
2nd Nov 202010:25 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.